Compare PGEN & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | PRQR |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 250.7M |
| IPO Year | N/A | 2014 |
| Metric | PGEN | PRQR |
|---|---|---|
| Price | $4.37 | $2.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $7.67 | ★ $8.14 |
| AVG Volume (30 Days) | ★ 3.9M | 604.4K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $6,309,000.00 | ★ $18,859,556.00 |
| Revenue This Year | $342.78 | N/A |
| Revenue Next Year | $478.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 59.20 | N/A |
| 52 Week Low | $0.67 | $1.07 |
| 52 Week High | $5.23 | $3.10 |
| Indicator | PGEN | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 64.73 | 49.00 |
| Support Level | $3.64 | $2.15 |
| Resistance Level | $3.75 | $2.49 |
| Average True Range (ATR) | 0.26 | 0.18 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 91.40 | 52.17 |
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.